http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Shun-Tung Yang,Weng-Sing Hwang,Tien-Wei Shyr 대한금속·재료학회 2013 METALS AND MATERIALS International Vol.19 No.6
The reverse transformation of the strain-induced martensite phase (α') to the austenite phase (γ) is studied in lightly and heavily cold-drawn 316 L stainless steel fibers using thermomagnetic analysis. The transformation mechanisms of the two types of fiber are different. A three-region reverse transformation process for α' to γ during the heating process in the two types of fiber is established. Throughout the reverse process, the transformation is dominated by a diffusion-controlled mechanism for the two types of fiber. Shear reversion occurs for the lightly cold-drawn 316 L fiber in region II. A shoulder appears in the TMA curve at around 625 °C for the heavily colddrawn 316 L fiber Transformations of existing α' and reformed α' via the diffusion-controlled and shear mechanisms occur in the temperature range of 625-640°C for the heavily cold-drawn 316L fiber. The transformation is attributed to the reformed α' containing low Nieq content, which retards the reverse transformation of the phase via shear mechanisms until around 625°C.
Li-Heng Yang,Hsin-Shun Tseng,Che Lin,Li-Sheng Chen,Shou-Tung Chen,Shou-Jen Kuo,Dar-Ren Chen 한국유방암학회 2012 Journal of breast cancer Vol.15 No.3
Purpose: This study aimed to analyze the efficacy and prognostic significance of adjuvant tamoxifen in breast cancer patients with various hormone receptor statuses. Methods: Typically, 1,260 female breast cancer patients were recruited in this study. The correlation between estrogen receptor (ER)/progesterone receptor (PR) phenotypes and clinical characteristics was investigated, and the survival rate was assessed after 5-year follow-up. Results: The 5-year overall survival (85%) was better in women under the age of 50 years. Patients with ER+/PR+ tumors had a better 5-year survival rate (94%); those with ER-/PR- tumors experienced the worst outcome (74% survival rate); whereas singlepositive cases were in between. In 97 out of 128 patients with ER-/PR+ tumors, tamoxifen was given as adjuvant hormonal therapy, and it increased the survival benefit in the lower grade group in terms of overall survival and disease-free survival (p=0.01 and p=0.03, respectively). Conclusion: For high-grade tumors with ER-/PR+, adjuvant tamoxifen therapy may have no survival benefit, whereas for the patients with low-grade ER-/PR+ tumors, adjuvant tamoxifen therapy is highly suggestive.